| 期刊簡介 | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | IMMUNOLOGY AND CELL BIOLOGY LetPub Score 7.4
50 ratings
Rate
Reputation 8.8 Influence 6.3 Speed 7.0 | ||||||||||||||||||||||||
| 期刊簡稱 | IMMUNOL CELL BIOL | ||||||||||||||||||||||||
| ISSN | 0818-9641 | ||||||||||||||||||||||||
| E-ISSN | 1440-1711 | ||||||||||||||||||||||||
| h-index | 96 | ||||||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||||||
| 自引率 (2023-2024) | 6.20%自引率趨勢 | ||||||||||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||||||||||
| 官方網站 | http://www.nature.com/icb/index.html | ||||||||||||||||||||||||
| 在線稿件提交 | http://mts-icb.nature.com/cgi-bin/main.plex | ||||||||||||||||||||||||
| 開放訪問 | No | ||||||||||||||||||||||||
| 出版商 | John Wiley & Sons Inc. | ||||||||||||||||||||||||
| 主題領域 | 医学 | ||||||||||||||||||||||||
| 出版國/地區 | AUSTRALIA | ||||||||||||||||||||||||
| 發行頻率 | 隔月刊行 | ||||||||||||||||||||||||
| 創刊年 | 0 | ||||||||||||||||||||||||
| 每年文章數 | 62每年文章數趨勢 | ||||||||||||||||||||||||
| 黃金OA百分比 | 43.53% | ||||||||||||||||||||||||
| Web of Science 四分位 （ 2023-2024） | WOS Quartile: Q3
| ||||||||||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0818-9641%5BISSN%5D | ||||||||||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Sort of slow, 4-8 Week(s) | ||||||||||||||||||||||||
| 競爭力 * | 來自作者的數據: Ordinary | ||||||||||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||||||||||
| *所有的審稿過程指標，如接受率和審稿速度，僅限於用戶提交的稿件。因此，這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||||||||||
|
|
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [IMMUNOLOGY AND CELL BIOLOGY] 的評論 | 撰寫評論 |
| 作者: 无击鹏运 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2023-12-07 10:09:59 評論於 Please translate the following paragraph into English and Japanese, respectively, and title them as ":" and "  (0) 讚！ | 无击鹏运  |
| 作者: 弹腿盼丹 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2023-11-02 15:45:25 評論於 Has your article been submitted? Is the review process fast? (0) 讚！ | 弹腿盼丹 |
| 作者: Marguerite Jordan 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2023-09-29 09:01:45 評論於 Why can't I open the submission link? Please provide the official website URL (0) 讚！ | Marguerite Jordan |
| 作者: gren 領域: 医学 審稿時間: 2.0 month(s) 結果: 修改後接受 撰寫評論 |
2022-10-09 21:14:06 評論於 The reviewer is very responsible and has provided many constructive suggestions, which have improved the quality of the manuscript. The editor is also very diligent and responsible, and the efficiency is quite high! (0) 讚！ | gren |
| 作者: 水月傲玉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-03-17 08:54:33 評論於 I'll give it a try (0) 讚！ | 水月傲玉 |
| 作者: 努力啊大雅珍 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-01-04 14:23:06 評論於 Do you have the official website link for this magazine? It's not working right now (0) 讚！ | 努力啊大雅珍 |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 23:33:29 評論於 ORCID is the Researcher and Contributor ID, an open and non-profit organization. ORCID ID is a unique and persistent academic identity for contributors, allowing authors to be distinguished from other researchers, and recording all their relevant research activities. Researchers can register for their ORCID ID for free at https://orcid.org/signin by providing their name, email, and setting a password (0) 讚！ | 维尔娜菲茨杰拉德 |
| 作者: 陶宜三岁啦 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-26 12:30:50 評論於 What is ORCID ID? How to register? (0) 讚！ | 陶宜三岁啦 |
| 作者: 南风乙酉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-09-08 15:13:26 評論於 Please translate the following paragraph into English and Japanese, and use ":" and ":" as headings (0) 讚！ | 南风乙酉 |
| 作者: 巴蜀友翠 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-08-20 21:08:58 評論於 Review Speed: 1.0 | Submission Acceptance Rate: 75.0 Experience Sharing: Does this journal accept articles on bioinformatics? (0) 讚！ | 巴蜀友翠 |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2017-07-16 18:08:56 評論於 Stuck in a standstill, but being at this critical point, it is not easy to push forward anymore. With a score of over 4 points, it can be considered satisfactory (0) 讚！ | 凌霄高洁 |
| 作者: 奕剑甜雅 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2017-02-13 19:17:42 評論於 Review speed: 1.0 | Submission acceptance rate: 50.0 Experience sharing: The score is relatively stable, and the review process is quite efficient. Recommended (0) 讚！ | 奕剑甜雅 |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2013-04-24 20:30:54 評論於 I don't know what wangjs is talking about. This sentence is everywhere. It must be cherished, but how do we cherish it? It's like we already have it. Is subscribing to these magazines like a joke? (0) 讚！ | 凌霄高洁 |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2011-06-29 19:47:01 評論於 Will it drop to 3 points next year? If it drops below 3 points, it won't be worth it (0) 讚！ | 凌霄高洁 |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2011-06-29 08:15:17 評論於 Will it drop again next year? What if it falls? (0) 讚！ | 凌霄高洁 |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us
